Skip to main content
. 2021 Sep 23;20(1):105–117. doi: 10.1007/s40258-021-00683-z
The COVID-19 pandemic shows that the impact of effective vaccines can extend well beyond vaccinated individuals and healthcare systems.
This study analysed to what extent the broader value of vaccines is considered in HTA and found a substantial gap between value generation and recognition.
Five priority areas for broader value recognition include considering (1) more comprehensive cost offsets within the health care system, (2) carer quality of life, (3) transmission value, (4) prevention of antimicrobial resistance and (5) macroeconomic effects.